Strategies for Optimizing Liposomal Doxorubicin

References

• Forssen E.A., Tokes Z.A. In vitro and in vivo studies with adriamycin liposomes. Biochem. Biophys. Res. Commun. 1979; 91: 1295–1301
   PubMed Web of Science ®Google Scholar
• Rahman A., Kessler A., More N., Sikic B., Rowden G., Woolley P., Schein P.S. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980; 40: 1532–1537
   PubMed Web of Science ®Google Scholar
• Forssen E.A., Tokes Z.A. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Natl. Acad. Sci. USA 1981; 78: 1873–1877
   PubMed Web of Science ®Google Scholar
• Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 1982; 42: 4734–4739
   PubMed Web of Science ®Google Scholar
• Olson F., Mayhew E., Maslow D., Rustum Y., Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol. 1982; 18: 167–176
   PubMedGoogle Scholar
• Herman E.H., Rahman A., Ferrans V.J., Vick J.A., Schein P.S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983; 43: 5427–5432
   PubMed Web of Science ®Google Scholar
• Rahman A., White G., More N., Schein P.S. Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped liposomes. Cancer Res. 1985; 45: 796–803
   PubMed Web of Science ®Google Scholar
• Gabizon A., Meshorer A., Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 1986; 77: 459–467
   Google Scholar
• Van Hossel Q.G.C.M., Steerenberg P.A., Crommelin D.J.A., van Dijk A., van Oost W., Klein S., Douze J.M.C., de Wildt D.J., Hillen F.C. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. Cancer Res. 1984; 44: 3698–3705
   PubMed Web of Science ®Google Scholar
• Forssen E.A., Tokes Z.A. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat. Rep. 1983; 67: 481–484
   PubMedGoogle Scholar
• Balazsovits J.A.E., Mayer L.D., Bally M.B., Cullis P.R., Ginsberg R.S., Falk R.E. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 1989; 23: 81–86
   Google Scholar
• Rahman A., Fumagalli A., Barbieri B., Schein P.S., Casazza A.M. Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Chemother. Pharmacol. 1986; 16: 21–27
   Google Scholar
• Gabizon A., Goren D., Fuks Z., Meshoren A., Barenholz Y. Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br. J. Cancer 1985; 51: 681–689
   PubMed Web of Science ®Google Scholar
• Mayhew E., Rustum Y.M. The use of liposomes as carriers of therapeutic agents. Prog. Clin. Biol. Res 1985; 172B: 301–312
   PubMedGoogle Scholar
• Mayhew E.G., Goldrosen M.H., Vaage J., Rustum Y.M. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 28. J. Natl. Cancer Inst. 1987; 78: 707–713
   PubMed Web of Science ®Google Scholar
• Forssen E.A., Tokes Z.A. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 1983; 43: 546–550
   PubMed Web of Science ®Google Scholar
• Storm G., Roerdink F.H., Steerenbeg P.A., de Jong W.H., Crommelin D.J.A. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res. 1987; 47: 3366–3372
   PubMed Web of Science ®Google Scholar
• Shinozawa S., Araki Y., Oda T. Tissue distribution and antitumor effect of liposome-entrapped doxorubicin (adriamycin) in Ehrlich solid tumor-bearing mouse. Acta Med. Okayama 1981; 35: 395–405
   PubMed Web of Science ®Google Scholar
• Kirby C., Clark J., Gregoriadis G. Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins. FEBS Lett. 1980; 111: 324–328
   PubMed Web of Science ®Google Scholar
• Scherphof G., Roerdink F., Waite M., Parks J. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high density lipoproteins. Biochim. Biophys. Acta 1978; 842: 296–307
   Web of Science ®Google Scholar
• Senior J., Gregoriadis G. Role of lipoproteins in stability and clearance of liposomes administered to mice. Biochem. Soc. Trans. 1984; 12: 339–340
   Google Scholar
• Baumier P.L., Hwang K.J. Effects of liposome size on the degradation of bovine brain sphingomyelin/cholesterol liposomes in mouse liver. Biochim. Biophys. Acta 1983; 731: 23–30
   Google Scholar
• Schroit A.J., Madsen J.W., Tanka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J. Biol. Chem. 1985; 260: 5131–5138
   PubMed Web of Science ®Google Scholar
• Senior J., Crawley J.C.W., Gregoriadis G. Tissue distribution of liposomes exhibiting long half lives in the circulation after intravenous injection. Biochim. Biophys. Acta 1985; 839: 1–8
   PubMed Web of Science ®Google Scholar
• Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987; 223: 42–46
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulous D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 1988; 85: 6949–6953
   PubMed Web of Science ®Google Scholar
• Hwang K.J. Liposome pharmacokinetics. Liposome: From Biophysics to therapeutics, M.J. Ostro. Marcel Dekker, New York 1987; 109–156
   Google Scholar
• Abra R.M., Hunt C.A. Liposome disposition in vivo: III Dose and vesicle size effects. Biochim. Biophys. Acta 1981; 666: 493–503
   PubMed Web of Science ®Google Scholar
• Bosworth M.E., Hunt C.A. Liposome disposition in vivo: II Dose dependency. J. Pharmacol. Sci. 1982; 71: 100–104
   PubMed Web of Science ®Google Scholar
• Beaumier P.L., Hwang K.J., Slattery J.T. Effect of liposome dose on the elimination of small unilamellar sphingomyelin/cholesterol vesicles from the circulation. Res. Commun. Chem. Pathol. Pharmacol. 1983; 39: 277–289
   Google Scholar
• Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedures: characterization of size, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 1985; 813: 55–65
   Google Scholar
• Mayer L.D., Hope M.J., Cullis P.R. Vesicles of various sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta 1986; 858: 161–168
   PubMed Web of Science ®Google Scholar
• Olson F., Hunt C.A., Szoka F.C., Vail W.J., Papahadjopoulous D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim. Biophys. Acta 1979; 557: 9–23
   PubMed Web of Science ®Google Scholar
• Rottenberg H. The measurement of membrane potential and ApH in cells, organelles and vesicles. Methods Enzymol. 1979; 15: 547–569
   Google Scholar
• Mayer L.D., Wong K.F., Menon K., Chong C.P., Harrigan R., Cullis P.R. Influence of ion gradients on the transbilayer distribution of dibucaine in large unilamellar vesicles. Biochemistry 1988; 27: 2053–2060
   PubMed Web of Science ®Google Scholar
• Redelmeier T.E., Mayer L.D., Wong K.F., Bally M.B., Cullis P.R. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys. J. 1989; 56: 385–393
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Bally M.B., Cullis P.R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 1986; 857: 123–126
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Tai L.C.L., Bally M.B., Mitilenes G.N., Ginsberg R.S., Cullis P.R. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta 1990; 1025: 143–151
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Tai L.C.L., Ko D.S.C., Masin D., Ginsberg R.S., Cullis P.R., Bally M.B. Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989; 49: 5922–5930
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Bally M.B., Hope M.J., Cullis P.R. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim. Biophys. Acta 1985; 816: 294–302
   PubMed Web of Science ®Google Scholar
• Minow R.A., Benjamin R.S., Gottlieb J.A. Adriamycin (NSC-123127)-cardiomyopathy: an overview with determination of risk factors. Cancer Chemother. Rep. 1975; 6: 195–201
   Google Scholar